Rates of late biochemical recurrence and progression to metastasis were “strikingly low” in patients with pT2 stage disease and Gleason scores less than or equal to 3 + 4.

Decitabine plus venetoclax and ponatinib appeared safe and elicited responses in a phase 2 trial of patients with advanced phase CML.

Using patient-derived tumor organoids, researchers have identified which therapies may be most effective for individual sarcoma patients.

(HealthDay News) — An in-home cognitive behavioral therapy program improves insomnia symptoms in breast cancer survivors, according to a study published in JAMA Network Open.